
· Executive Brief
Fungal Disease Awareness Week 2026
A practical executive framework for access, ownership, handoffs, measurement, and improvement.

Leadership signal
Fungal Disease Awareness Week can serve as an executive operating checkpoint.
Awareness can generate questions and requests for help. Executive teams can prepare by clarifying the first point of contact, the qualified team that accepts the request, the handoff standard, and the method used to verify completion without assuming that one route fits every person.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Fungal disease is a recognition and readiness problem before it is a treatment problem
Fungal infections rarely announce themselves. Patients with endemic fungal pneumonia often look like patients with ordinary community-acquired pneumonia, and drug-resistant yeasts can spread silently through units before anyone suspects them. For health-system leaders, that makes fungal disease a test of how well the organization notices what it is not looking for. Fungal Disease Awareness Week offers a structured moment to examine that capacity across outpatient, laboratory and inpatient services.
The evidence shows the cost of not noticing. A national claims analysis estimated that almost 60% of patients with coccidioidomycosis had at least one missed opportunity for diagnosis, with an average diagnostic delay of 29.69 days.[1] Among 573,994 adult outpatients with unspecified community-acquired pneumonia, only 25,822 underwent fungal diagnostic testing.[2] These are not failures of individual clinicians alone. They reflect ordering defaults, laboratory access and the absence of prompts that would make testing routine when the clinical picture fits.
Hospital infection control faces a parallel challenge with Candida auris. A national survey of Canadian surveillance hospitals found that policy presence for C. auris rose from 18% to 73% among hospitals answering in both 2018 and 2024, yet practice still varied.[5] Preparedness improved, but the authors linked remaining variation to evidence gaps and resource constraints.[5]
This brief adds the research base behind the executive guidance on this page. It covers the burden of delayed diagnosis, the transitions where resistant organisms move, access to testing, equity, the teams that make stewardship and containment work, and how leaders can communicate about fungal risk without alarm. Each section names the evidence, its limits and the operational question it raises for leaders. The goal is not a new campaign, but a more reliable system for recognizing and containing fungal disease.
Current evidence
What the research says about delay, testing and severity
Diagnostic delay is common and measurable. Using insurance claims from 2001 to 2022 and a case-crossover design, researchers estimated the number of excess symptom visits before a coccidioidomycosis diagnosis.[1] Missed opportunities were concentrated in outpatient settings, which accounted for 73% of them.[1] They were significantly associated with older age, rural residence, underlying pulmonary conditions and prescriptions for antibiotics or inhalers.[1]
That last association matters for operations. A patient who receives antibiotics or an inhaler for a respiratory illness may appear to have been managed, while the actual cause remains untested. A second national cohort found that fungal testing, when it occurred, came a median of 3 health care visits after the initial pneumonia diagnosis.[2] Among tested patients, 755 (3%) received a blastomycosis, coccidioidomycosis or histoplasmosis diagnosis code.[2] The authors described testing rates as low in many locations.[2]
Delay carries the greatest weight in patients with fragile health. A retrospective cohort of 46 adults with cirrhosis and coccidioidomycosis at a tertiary center in California’s San Joaquin Valley reported a median diagnostic delay of 28 days.[3] Hospitalization was required in 63%, ICU care in 24%, and all-cause mortality was 33%.[3] Hepatotoxicity occurred in 26% of patients, and the authors count treatment complications among the features of this high-risk syndrome.[3] Relapse occurred in 24%, and the median time to death was 369 days.[3]
Laboratory data show that demand for fungal testing is growing. A retrospective review of a laboratory network tested 2,442 urine samples for Histoplasma antigen between February 2021 and August 2023.[4] Testing rates increased over time and peaked in the first quarter of 2023, when 358 tests were performed and 25 specimens tested positive (7%).[4] Positivity and antigen concentration were higher in adults than in patients younger than 18 years.[4]
For Candida auris, the evidence highlights the limits of routine precautions. A meta-analysis comparing 7 international guidelines with data from 23 outbreak cohorts found a pooled failure and recontamination proportion of 0.708 when standard contact precautions and episodic disinfection were used alone.[6] Proactive containment strategies were associated with a 79% reduction in transmission risk.[6] Admission rapid molecular screening and withdrawal of reusable clinical items were among the strongest associations, as later sections describe.[6]
Figure 1
Fungal disease leaks at recognition, severity and containment
Percent as reported in each study (share of missed opportunities, patients or samples). Values are copied from the cited studies [1], [3], [5], [7]; none is estimated.
Data note. These values come from different studies, countries, years and denominators, so this is an indirect comparison; the bars show where the system is exposed, not how one risk ranks against another.
Limitation. Each value reflects its own setting; the outpatient share is a share of missed opportunities, not of patients, and the contamination value applies to outbreak wards only.
Figure data (4 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Missed coccidioidomycosis diagnostic opportunities occurring in outpatient settings | 73% | U.S. insurance claims, 2001 to 2022 | [1] |
| Patients with cirrhosis and coccidioidomycosis who required hospitalization | 63% | 46 adults at one tertiary center in California, 2010 to 2025 | [3] |
| Canadian hospitals with C. auris admission screening policies | 80% | 87 of 109 surveillance network hospitals, June 2024 | [5] |
| Air grille samples contaminated with C. auris during outbreaks | 31.6% | Acute and convalescent hospital in Hong Kong, March to October 2023; 10.2% for high-touch surfaces | [7] |

Continuum of care
Where resistant fungi move across units, hospitals and regions
Candida auris travels with patients. A molecular study of 33 clinical isolates from 19 patients in Shanghai concluded that ICU patients served as primary reservoirs and that transmission was driven by interregional movement.[12] All 33 isolates were fluconazole-resistant, and colonization concentrated in the urinary tract and inguinal regions.[12] Every transfer, readmission and interfacility move is therefore a moment when screening status must travel with the patient. Transfer centers and receiving units need a reliable way to see that status before a bed is assigned.
Admission screening is one of the clearest transition controls. Most Canadian surveillance hospitals had policies for admission screening (80%, 87/109) and policies or defined plans for post-exposure screening (95%, 104/109).[5] Among Canadian hospitals with admission screening policies, 69% (60/87) screened patients for recent out-of-country hospitalization.[5] Practice after exposure varied more. Overall, 94% (99/105) of hospitals without exclusively private rooms screened roommates, while 55% (60/109) of hospitals screened wardmates.[5] Leaders should ask which of these triggers their own organization applies and how reliably.
Large systems can introduce screening in stages. One acute care hospital system implemented a phased C. auris screening program based on high-risk criteria from the Centers for Disease Control and Prevention.[9] The program identified C. auris early in the hospital stay, and interdisciplinary collaboration supported continuous improvement of screening and isolation workflows.[9] Early identification protects the units a patient passes through after admission. A phased rollout also gives leaders a chance to test screening workflows on a few units before extending them system-wide.
Transitions also happen inside a single hospital when units change how they isolate patients. In an 87-week interrupted time series, discontinuing dedicated cohort units did not increase adjusted screening positivity, while later enhanced nursing engagement was associated with lower positivity.[10] The authors emphasized clear screening and isolation workflows when cohorting is de-escalated.[10] For executives, the lesson is that any change in isolation strategy should be paired with a clear workflow and frontline involvement.
Newly affected centers face a steep learning curve. A four-month review of the first locally documented C. auris cases at one center identified 14 clinical cases and reported a mortality rate of 71.4%.[13] After an infection control protocol was implemented, no further C. auris was detected in environmental samples.[13] Clinical cases continued to occur, though at a decreasing frequency.[13]
Figure 3
Why the pathway breaks
People
- Clinicians outside endemic areas rarely consider fungal causes
- Limited infectious diseases pharmacist capacity at smaller hospitals
- Frontline nurses not engaged in screening workflow design
Process
- Pneumonia treated with repeated antibiotics before testing
- Admission screening triggers applied inconsistently
- Exposed roommates and wardmates not always screened
Technology
- Laboratory unable to identify Candida to species level
- No ordering prompt for fungal testing in outpatient records
- Screening status not carried with transfer records
Environment
- Air grilles overlooked during decontamination
- Shared mobile equipment such as SpO2 probes and transfer boards
- Patient movement between regions and facilities
Policy
- Precaution and screening rules differ between neighboring hospitals
- Resource constraints limit preparedness
- No standard framework for antifungal stewardship
Measurement
- Time to fungal diagnosis not tracked
- Testing rates not stratified by geography or age
- Environmental findings not reported to leadership
Unranked qualitative cause-and-effect diagram for the outcome in the box: Fungal infections are recognized late and resistant fungi spread before containment begins Causes are assembled from the cited literature [1], [2], [5], [7], [8], [10], [14]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Clinicians outside endemic areas rarely consider fungal causes; Limited infectious diseases pharmacist capacity at smaller hospitals; Frontline nurses not engaged in screening workflow design |
| Process | Pneumonia treated with repeated antibiotics before testing; Admission screening triggers applied inconsistently; Exposed roommates and wardmates not always screened |
| Technology | Laboratory unable to identify Candida to species level; No ordering prompt for fungal testing in outpatient records; Screening status not carried with transfer records |
| Environment | Air grilles overlooked during decontamination; Shared mobile equipment such as SpO2 probes and transfer boards; Patient movement between regions and facilities |
| Policy | Precaution and screening rules differ between neighboring hospitals; Resource constraints limit preparedness; No standard framework for antifungal stewardship |
| Measurement | Time to fungal diagnosis not tracked; Testing rates not stratified by geography or age; Environmental findings not reported to leadership |
Access
Making fungal testing and stewardship expertise available where decisions are made
Access to fungal diagnosis depends on whether a test is ordered, whether the laboratory can run it, and whether results return in time to change care. The national pneumonia cohort showed that most patients never reached the first step.[2] Rash, chest pain, lymphadenopathy, myalgia and receipt of antibiotics from multiple classes were each independently associated with a coccidioidomycosis diagnosis among tested patients.[2] Those features could inform ordering prompts in outpatient and urgent care settings. Prompts should be designed with infectious diseases clinicians so they target patients with relevant exposure rather than every respiratory visit.
Laboratory capacity is the second gate. In the Canadian survey, 81% (26/32) of microbiology laboratories identified all clinically significant Candida isolates to species level.[5] That share rose from 48% to 85% among the 27 laboratories that completed both the 2018 and 2024 surveys.[5] Twenty-four laboratories (75%) had standard operating procedures for processing screening specimens.[5] Without species-level identification, C. auris can be reported as a less concerning yeast.
Diagnostic methods also shape access. A center reporting its first C. auris cases used several identification systems to confirm isolates and stressed the critical importance of accurate identification.[13] In Shanghai, investigators recommended integrating PCR-based environmental monitoring with culture methods as an effective strategy.[12] Antigen testing for histoplasmosis is another access question, since testing rates increased over time in the laboratory network review.[4] Smaller hospitals that send out these tests should know the expected turnaround time.
Stewardship expertise is a form of access too. At one community hospital, a 0.6 full-time equivalent infectious diseases pharmacist team was associated with an estimated net return of about $323K, based on roughly $639K in avoided antibiotic costs against $316K invested.[14] Total antimicrobial use, which included antifungals, decreased by 11.6%.[14] Smaller hospitals often lack this expertise entirely, so a modest pharmacist investment may extend specialist judgment to more patients.
Each of these gates can be measured. Leaders can track the share of eligible pneumonia patients tested, the time from specimen collection to species identification, and stewardship pharmacist coverage at each hospital. Where a gate depends on a reference laboratory, contracts should specify turnaround times and escalation for critical results. These are management choices, and they determine whether a patient’s first visit can become the diagnostic visit.
Executive guidance · System route
Build one visible operating route for Fungal Disease Awareness Week.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Align prevention and response
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Align prevention and response
Connect approved prevention communication, qualified response, escalation, documentation, and partner coordination under local policy and applicable requirements.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Align prevention and response | Connect approved prevention communication, qualified response, escalation, documentation, and partner coordination under local policy and applicable requirements. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Who waits longest for a fungal diagnosis
Diagnostic delay is not evenly distributed. In the national coccidioidomycosis analysis, rural residence and older age were each significantly associated with missed diagnostic opportunities.[1] Rural patients may see clinicians with less exposure to endemic fungi, travel farther for imaging and specialty care, and rely on outpatient sites with fewer laboratory options. These patterns call for equity analysis by geography, not only by demographics.
Clinical vulnerability compounds geographic risk. In the San Joaquin Valley cirrhosis cohort, 67% of patients identified as Hispanic and 67% had decompensated cirrhosis.[3] Alcohol-related liver disease was the most common cause.[3] The authors called for early recognition and optimized antifungal management for this vulnerable population.[3] Liver disease programs in endemic regions may be a practical place to look for missed fungal diagnoses. Hepatology, primary care and infectious diseases teams in endemic regions share responsibility for that recognition.
Testing gaps also vary by place. The national pneumonia cohort described testing rates for blastomycosis, coccidioidomycosis and histoplasmosis as low in many locations.[2] Patients outside known endemic areas, including travelers and people who have moved, may be least likely to be tested. Clinicians may not consider exposure histories that fall outside local experience. Health systems can review testing rates by site, payer and patient geography to see whether access to fungal diagnostics follows the population at risk.
Resource-limited settings show that stewardship can work without large budgets. In a quasi-experimental study at a cardiac center in Egypt, documented fungal infections fell from 12 before stewardship implementation to 6 afterward, although the change was not statistically significant (p = 0.236).[15] Colistin use declined significantly, from 817 to 53 defined daily doses per 1,000 patient days.[15] Klebsiella pneumoniae infections also decreased significantly, from 42 to 19 isolates.[15] The authors highlighted the program’s potential value in resource-limited settings.[15]
Equity work in this area depends on trust between patients and the systems that screen them. In the Canadian survey, 70% (76/109) of hospitals continued precautions for C. auris cases indefinitely.[5] Leaders should weigh what indefinite precautions mean for patient experience. Leaders should review whether precaution policies are applied consistently and explained clearly to patients and families. Isolation policies should balance transmission control with the dignity, mobility and recovery needs of each patient.

Human infrastructure
The teams that find, contain and steward fungal disease
Fungal disease readiness depends on teams that rarely sit together: infection preventionists, microbiologists, pharmacists, nurses, environmental services staff and clinicians in outpatient care. Each group holds part of the answer, and none can contain an outbreak alone. When a nosocomial C. auris outbreak affected cardiac surgery patients at one academic hospital, the response combined an expanded epidemiological line listing, enhanced surveillance, environmental culturing, whole-genome sequencing and an in-house PCR assay.[11] This integrated approach achieved sustained interruption of transmission.[11]
Frontline nursing engagement carries measurable weight. In the 87-week interrupted time series, enhanced nursing engagement was associated with lower screening positivity, and the authors called for sustained frontline engagement.[10] Nurses perform screening swabs, maintain isolation and notice when workflows break down. Their participation in design is a practical requirement, not a courtesy. Float staff and agency nurses need the same screening and isolation preparation as permanent unit staff.
Environmental services teams need precise targets. In two Hong Kong hospitals, air grille samples had a significantly higher contamination rate than high-touch surfaces in the outbreak group (31.6% vs 10.2%).[7] Environmental contamination was also higher in outbreaks than in sporadic cases (15.1% vs 2.6%), and higher contamination was associated with longer outbreak duration (34 vs 7 days).[7] Air grilles are often overlooked during decontamination.[7]
Equipment handling is a shared responsibility that often has no single owner. Across five ICU cluster responses in one hospital, 9 of 177 environmental sampling records were culture-positive for C. auris (5.1%).[8] SpO2 probes and clips accounted for four positive records, and other positive sites included a transfer board and a soiled-linen cart.[8] The meta-analysis found that targeted withdrawal of highly handled, reusable clinical items had the highest outbreak-termination efficacy (RR, 0.08).[6] Environmental categories in the ICU study were defined partly by cleaning responsibility, and the authors flag equipment assignment and between-patient disinfection for review.[8]
Pharmacists anchor stewardship. The community hospital pharmacist team was also associated with a 75.6% decrease in carbapenem use and a 63% decrease in the incidence rate of hospital-onset Clostridioides difficile infection.[14] Fluoroquinolone use decreased by 57.9% over the same comparison.[14] These results come from a descriptive single-site evaluation, so they show what a small team can accomplish rather than a guaranteed return.[14]
Executive guidance · Operating dashboard
Use a small dashboard to expose friction and ownership.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Prevention-to-response reliability
Do approved prevention messages connect to real response capacity and named ownership?
- Candidate local measure
- Locally defined readiness barriers, unowned inquiries, unresolved escalations, process exceptions, and corrective actions.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Prevention-to-response reliability | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Close the loop across teams, settings, and partners.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Transfer concerns to the locally designated qualified owner and preserve visibility through acknowledgment.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Give leaders one view of route reliability and improvement.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Prevention-to-response reliability | Do approved prevention messages connect to real response capacity and named ownership? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for fungal recognition, stewardship and containment
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Fungal testing prompt for unresolved pneumonia in endemic or exposed patients | Repeated visits and antibiotics before diagnosis | Chief medical officer with ambulatory leadership | Share of eligible pneumonia patients tested and median visits before testing |
| Species-level identification of clinically significant Candida isolates | C. auris reported as a routine yeast | Laboratory director | Documented identification method and turnaround time |
| Admission screening using defined high-risk criteria | Colonized patients placed in open units | Infection prevention lead | Screening completion rate among patients meeting criteria |
| Screening status carried on every transfer | Exposure spreads to receiving units and facilities | Patient flow and transfer center leads | Audit of transfer records that include screening status |
| Cleaning ownership for reusable mobile equipment and air grilles | Persistent environmental reservoirs | Environmental services director | Environmental culture results during cluster responses |
| Antimicrobial stewardship coverage including antifungals | Inappropriate antifungal use and resistance | Pharmacy and stewardship committee | Days of therapy per 1,000 days present reviewed quarterly |
Control points derived from the cited evidence [2], [5], [7], [8], [9], [14] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communicating fungal risk to clinicians, patients and the public
The most important audience for fungal disease awareness may be clinicians. The authors of the national pneumonia cohort concluded that increased awareness of these infections may help increase timely testing, decrease health care utilization and reduce inappropriate antibiotic use.[2] Awareness campaigns inside a health system can focus on specific triggers, since missed opportunities were associated with prescriptions for antibiotics or inhalers.[1] Short case reviews at grand rounds, built from the organization’s own delayed diagnoses, can make that message concrete.
Communication with patients should explain why testing matters without creating fear. Patients in endemic regions can be told that some respiratory illnesses come from fungi in soil and that a specific test may be needed. Messages should be reviewed with infectious diseases experts and adapted to local exposure patterns, literacy and language. Plain-language materials should also explain what a positive screening result for C. auris means for visitors and family caregivers. The claims analyses show that patients often return several times before a fungal cause is identified.[1][2]
Outbreak communication requires honesty and coordination. The Canadian survey found that frequency and timing of screening and policies on precautions for exposed patients varied across hospitals.[5] When neighboring hospitals follow different rules, patients and families receive mixed messages during transfers. Shared transfer forms and agreed language for screening status are simple tools that support consistency. Regional coordination among infection prevention teams can reduce that confusion and support consistent public explanations.
Governance turns communication into accountability. The meta-analysis found that admission rapid molecular screening was associated with reduced transmission risk (RR, 0.19), supporting a shift toward diagnostic acceleration.[6] Boards and quality committees can ask for regular reports on time to fungal diagnosis, laboratory identification capability, screening coverage and environmental findings. Each measure should carry a named owner and a clear definition. Those reports should compare results over time within the organization rather than against external benchmarks that use different definitions.
Finally, leaders should describe progress carefully. Several studies in this brief are single-site, retrospective or descriptive, and associations do not establish that one intervention produced an outcome.[11][13][15] Reporting what changed, what was measured and what remains uncertain will build more durable trust than claims of success after a single quiet month. Fungal Disease Awareness Week is a useful prompt for that kind of disciplined, transparent reporting.

Executive guidance · 90-day plan
Turn the observance into one sustained operating change.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how Fungal Disease Awareness Week communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one prevention-to-response route against local policy and correct a verified readiness or ownership gap.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how Fungal Disease Awareness Week communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one prevention-to-response route against local policy and correct a verified readiness or ownership gap. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Make Fungal Disease Awareness Week a starting point, not an endpoint.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Make ownership visible, test the route, and report what improved.
Executive action kit · Week observance
Turn Fungal Disease Awareness Week into accountable action.
A practical executive framework for access, ownership, handoffs, measurement, and improvement.
Leadership focus
Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, prevention, readiness, and response pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review language access, digital access, transportation, trust, and other barriers that may affect prevention information or connection to approved services.
Five-minute briefing
Inspect the operating sequence
Listen with infection prevention, clinical teams, operations, communications, and community-facing partners. Find one conflicting guidance, unclear entry points, or delayed escalation, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Align prevention and response
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined readiness barriers, unowned inquiries, unresolved escalations, process exceptions, and corrective actions.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Public Health and Community Partners
Staff communication template
During Fungal Disease Awareness Week, our organization will connect awareness with a practical review of the information, prevention, readiness, and response pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
Fungal Disease Awareness Week is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Barber DD, Arakkal AT, Thompson GR, Baddley JW, Cavanaugh JE, Miller AC, et al. Frequency and Duration of Diagnostic Delays Associated with Coccidioidomycosis and Risk Factors for Missed Diagnoses, United States. Emerging Infectious Diseases. 2026;32(5):697-706. https://doi.org/10.3201/eid3205.251421
- 2.Benedict K, Thompson GR, Ampel NM, Smith DJ, Toda M, Hennessee I. Blastomycosis, Histoplasmosis, and Coccidioidomycosis in Outpatient Community-Acquired Pneumonia. JAMA Network Open. 2026;9(1):e2553965. https://doi.org/10.1001/jamanetworkopen.2025.53965
- 3.Nukala N, Shepard R, Iqbal H, Mehmood BF, Huynh N, Golston AC, et al. Coccidioidomycosis in cirrhosis: A high-risk syndrome with severe outcomes. The American Journal of the Medical Sciences. 2026. https://doi.org/10.1016/j.amjms.2026.01.009
- 4.Gómez JC, Cáceres DH. Histoplasma antigen detection: A laboratory-based retrospective review of routine testing from 2021 to 2023. Biomedica. 2026;46(Sp. 1):141-151. https://doi.org/10.7705/biomedica.7866
- 5.Tan C, Bharat A, McGill E, Mitchell R, Varsaneux O, Cannon K, et al. Preparedness for Candida auris in Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals, 2024. Infection Control and Hospital Epidemiology. 2026;47(1):39-45. https://doi.org/10.1017/ice.2025.10228
- 6.Acosta-España JD, Flores-Roman PA, Vásquez-Chiriboga NS. Efficacy of standard precautions versus proactive containment for nosocomial Candida auris outbreaks: a systematic review and meta-analysis. Journal of Hospital Infection. 2026;173:115-122. https://doi.org/10.1016/j.jhin.2026.04.011
- 7.Fung WY, Cheng RYF, Yau APY, Lee SY, Chan NH, Wong YS, et al. Long-range air dispersal as an important source of environmental contamination in Candida auris clustering: possible infection control implication. Infection Control and Hospital Epidemiology. 2026;47(1):46-52. https://doi.org/10.1017/ice.2025.10347
- 8.Wang H, Zhang K, Liao T, Cao H, Wang P. Surface-associated Candida auris recovery during five intensive care unit cluster responses: a retrospective descriptive study with structured evidence mapping. Frontiers in Cellular and Infection Microbiology. 2026;16:1955493. https://doi.org/10.3389/fcimb.2026.1955493
- 9.Wentland West A, Macsay E, Snure KJ, Northern WI. A phased approach to implementation of a Candida auris screening program in a large, acute care hospital system. American Journal of Infection Control. 2026;54(1):66-70. https://doi.org/10.1016/j.ajic.2025.09.003
- 10.Turner D, DeMaet MA, Bundage D, Lisan A, Amaya A, Shockley L, et al. Candida auris screening positivity after discontinuation of cohort units and enhanced nursing engagement: An interrupted time series. American Journal of Infection Control. 2026;54(10):1117-1119. https://doi.org/10.1016/j.ajic.2026.06.001
- 11.Vacca ML, Persaud RR, Evans JS, Ehly M, Flomenberg PR, Leahy M, et al. Candidozyma auris (formerly Candida auris) in the acute care environment: Identifying and controlling transmission through a systematic investigation in an academic hospital. American Journal of Infection Control. 2026;54(9):1033-1035. https://doi.org/10.1016/j.ajic.2026.04.017
- 12.Wei M, Guo J, Li L, Zhu J, Xue Y, Chen G, et al. The Epidemiology and Infection Control of Candida Auris in Shanghai. Mycoses. 2026;69(4):e70176. https://doi.org/10.1111/myc.70176
- 13.Uğur M, Sarp ME, Altun Sarp S, Yetkin MA, Koç AN, Mutlu Sarıgüzel F. Candidozyma auris: A retrospective analysis of diagnostic challenges, antifungal susceptibility, and infection control measures. Journal de Mycologie Medicale. 2026;36(2):101622. https://doi.org/10.1016/j.mycmed.2026.101622
- 14.Casalini JM, Steenhoek R, Iaderosa B, Perry E, Richter LM. Antimicrobial Stewardship and Financial Outcomes Following Implementation of an Infectious Diseases Pharmacist Team at a Community Hospital. Hospital Pharmacy. 2026:1. https://doi.org/10.1177/00185787261485531
- 15.Morsi N, Mosaad E, Ahmed O. Evaluating the effects of antimicrobial stewardship program on antimicrobial consumption and resistance patterns: a quasi-experimental study. BMC Infectious Diseases. 2026;26(1). https://doi.org/10.1186/s12879-026-13358-8
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Frequency, duration and risk factors for missed coccidioidomycosis diagnoses | [1] | 2026 | Current evidence | Commercial claims data; case-crossover estimates of excess visits rather than chart-confirmed delays. |
| Fungal testing among outpatients with community-acquired pneumonia | [2] | 2026 | Current evidence | Claims-based cohort; diagnosis codes may not confirm disease; commercially insured population. |
| Outcomes of coccidioidomycosis in cirrhosis | [3] | 2026 | Current evidence | Single tertiary center, 46 patients, retrospective record review. |
| Histoplasma antigen testing volumes and positivity | [4] | 2026 | Current evidence | One laboratory network; headline positivity figures were not used because the abstract reports them inconsistently. |
| Standard precautions versus proactive containment for C. auris | [6] | 2026 | Current evidence | Outbreak cohorts are heterogeneous and largely observational; pooled estimates carry wide intervals. |
| Patient movement, admission screening and transfer controls | [5] [9] [12] | 2026 | Continuum of care | Survey self-report, a descriptive implementation account and a single-city molecular study. |
| Cohort de-escalation and nursing engagement | [10] | 2026 | Continuum of care | Single-system interrupted time series; brief report without full effect sizes in the abstract. |
| Laboratory identification capacity and diagnostic methods | [5] [12] [13] | 2026 | Access | Canadian survey and single-center laboratory studies; capacity may differ in U.S. hospitals. |
| Stewardship staffing, antimicrobial use and financial return | [14] [15] | 2026 | Access | Single-site descriptive and quasi-experimental designs; fungal outcomes not statistically significant. |
| Geographic and demographic risk for delayed diagnosis | [1] [2] [3] | 2026 | Equity and trust | Associations from observational data; race and ethnicity reported only in the single-center cohort. |
| Environmental and equipment reservoirs during clusters | [7] [8] | 2026 | Human infrastructure | Purposive sampling; isolate relatedness not assessed in the ICU equipment study. |
| Integrated outbreak investigation | [11] | 2026 | Human infrastructure | Single academic hospital report without quantitative outcomes in the abstract. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

